Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.

Tillner J, Posch MG, Wagner F, Teichert L, Hijazi Y, Einig C, Keil S, Haack T, Wagner M, Bossart M, Larsen PJ.

Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16.

PMID:
30091218
2.

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M.

Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514.

3.

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL.

Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A, Klinger M.

Exp Hematol Oncol. 2017 May 18;6:14. doi: 10.1186/s40164-017-0074-5. eCollection 2017.

4.

A systematic review of prehabilitation programs in abdominal cancer surgery.

Hijazi Y, Gondal U, Aziz O.

Int J Surg. 2017 Mar;39:156-162. doi: 10.1016/j.ijsu.2017.01.111. Epub 2017 Feb 2. Review.

5.

Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.

Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M.

CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):507-15. doi: 10.1002/psp4.12003. Epub 2015 Aug 22.

6.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P.

Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.

PMID:
22592608
7.

Volume ray casting with peak finding and differential sampling.

Knoll A, Hijazi Y, Westerteiger R, Schott M, Hansen C, Hagen H.

IEEE Trans Vis Comput Graph. 2009 Nov-Dec;15(6):1571-8. doi: 10.1109/TVCG.2009.204.

PMID:
19834235
8.

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CE, Stingl G, Jung T.

J Clin Invest. 2008 Sep;118(9):3151-9. doi: 10.1172/JCI35636.

9.
10.

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.

Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D.

Xenobiotica. 2007 Oct-Nov;37(10-11):1331-54. Review.

PMID:
17968748
11.

Pharmacokinetic-pharmacodynamic modelling of ketamine in six neurotraumatised intensive care patients.

Hijazi Y, Bodonian C, Salord F, Bressolle F, Boulieu R.

Clin Drug Investig. 2003;23(9):605-9. No abstract available.

PMID:
17535074
12.

Physics of perpendicular recording with a patterned soft underlayer.

Khizroev S, Hijazi Y, Amos N, Felissaint E, Joshi N, Ikkawi R, Chomko R, Litvinov D.

J Nanosci Nanotechnol. 2007 Jan;7(1):243-54. Review.

PMID:
17455488
13.

Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers.

Hijazi Y, Welker H, Dorr AE, Frank K, Renzetti LM, Patel I.

Eur J Clin Pharmacol. 2006 Jan;62(1):83-5. Epub 2005 Dec 21. No abstract available.

PMID:
16369813
14.
15.

Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury.

Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R.

Br J Anaesth. 2003 Feb;90(2):155-60.

16.

Ectopic pregnancy in Conakry, Guinea.

Thonneau P, Hijazi Y, Goyaux N, Calvez T, Keita N.

Bull World Health Organ. 2002;80(5):365-70.

17.
18.

Protein binding of ketamine and its active metabolites to human serum.

Hijazi Y, Boulieu R.

Eur J Clin Pharmacol. 2002 Apr;58(1):37-40. Epub 2002 Mar 12.

PMID:
11956671
19.

Adult T-cell leukemia/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study.

Dahmoush L, Hijazi Y, Barnes E, Stetler-Stevenson M, Abati A.

Cancer. 2002 Apr 25;96(2):110-6.

20.

Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples.

Hijazi Y, Bolon M, Boulieu R.

Clin Chem. 2001 Sep;47(9):1713-5. No abstract available.

21.

Seroprevalence of West Nile, Rift Valley, and sandfly arboviruses in Hashimiah, Jordan.

Batieha A, Saliba EK, Graham R, Mohareb E, Hijazi Y, Wijeyaratne P.

Emerg Infect Dis. 2000 Jul-Aug;6(4):358-62.

22.

Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior.

Parham DM, Hijazi Y, Steinberg SM, Meyer WH, Horowitz M, Tzen CY, Wexler LH, Tsokos M.

Hum Pathol. 1999 Aug;30(8):911-8.

PMID:
10452503
24.

Metastatic mesothelioma presenting as a salivary gland neoplasm.

Sgrignoli A, Abati A, Pass H, Lebovics R, Hijazi Y.

Acta Cytol. 1998 May-Jun;42(3):818-20. No abstract available.

PMID:
9622718
26.

Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity.

Kim CJ, Cormier J, Roden M, Gritz L, Mazzara GP, Fetsch P, Hijazi Y, Lee KH, Rosenberg SA, Marincola FM.

Ann Surg Oncol. 1998 Jan-Feb;5(1):64-76.

PMID:
9524710
27.

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.

Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM.

Int J Cancer. 1998 Feb 9;75(4):517-24.

28.

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL.

J Immunother. 1998 Jan;21(1):27-31.

PMID:
9456433
29.

Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.

Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, Weng DE, Roros JG, Hijazi YM, Xu S, Rosenberg SA, Cohen PA.

J Immunol. 1997 Oct 15;159(8):3823-37.

PMID:
9378970
30.

Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas.

Fetsch PA, Cormier J, Hijazi YM.

J Immunother. 1997 Jan;20(1):60-4.

PMID:
9101414
31.

Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.

Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ.

Cancer J Sci Am. 1996 Sep-Oct;2(5):263-72.

PMID:
9166543
32.

Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.

Wexler LH, DeLaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L, Jacobson J, Jarosinski P, Hijazi YM, Balis FM, Horowitz ME.

Cancer. 1996 Aug 15;78(4):901-11. Erratum in: Cancer 1997 Feb 15;79(4):867.

PMID:
8756388
33.

Application of molecular techniques to the diagnosis of microsporidial infection.

Fedorko DP, Hijazi YM.

Emerg Infect Dis. 1996 Jul-Sep;2(3):183-91. Review.

34.

Oncocytic nodular hidradenoma.

Roth MJ, Stern JB, Hijazi Y, Haupt HM, Kumar A.

Am J Dermatopathol. 1996 Jun;18(3):314-6.

PMID:
8806968
35.

Cytologic effects of photodynamic therapy in body fluids.

Garza OT, Abati A, Sindelar WF, Pass HI, Hijazi YM.

Diagn Cytopathol. 1996 Jun;14(4):356-61.

PMID:
8725138
36.

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):192-205.

PMID:
8811494
37.

Pulmonary and ovarian manifestations of systemic mastocytosis.

Avila NA, Worobec AS, Ling A, Hijazi Y, Metcalfe DD.

AJR Am J Roentgenol. 1996 Apr;166(4):969-70. No abstract available.

PMID:
8610583
38.

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC.

Ann Intern Med. 1996 Mar 1;124(5):477-84.

PMID:
8602705
39.

Mantle cell lymphoma: a cytopathological and immunocytochemical study.

Gagneten D, Hijazi YM, Jaffe ES, Solomon D.

Diagn Cytopathol. 1996 Feb;14(1):32-7.

PMID:
8834074
40.

Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy.

Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME, Tsokos M.

Am J Clin Pathol. 1994 Jul;102(1):61-7.

PMID:
7913576
41.

Metastatic epithelioid hemangioendothelioma in a pleural effusion: diagnosis by cytology.

Abati A, Cajigas A, Hijazi YM.

Diagn Cytopathol. 1994;11(1):64-7.

PMID:
7956664
42.

Fine needle aspiration cytology of submucosal nodules in patients with Zollinger-Ellison syndrome.

Benya RV, Metz DC, Hijazi YJ, Fishbeyn VA, Pisegna JR, Jensen RT.

Am J Gastroenterol. 1993 Feb;88(2):258-65.

PMID:
8093826
44.

Disseminated histoplasmosis in a renal transplant patient: a cause of renal failure several years following transplantation.

Sridhar NR, Tchervenkov JI, Weiss MA, Hijazi YM, First MR.

Am J Kidney Dis. 1991 Jun;17(6):719-21.

PMID:
2042657
45.

A follow-up study of former residents of a therapeutic community.

Collier WV, Hijazi YA.

Int J Addict. 1974;9(6):805-26. No abstract available.

PMID:
4448560

Supplemental Content

Loading ...
Support Center